The drug law enforcement agency of India, Narcotics Control Bureau within the revenue wing of the Union Finance Minister, has authorized a research and development (R&D) program on Cannabidiol (CBD) and Tetrahydrocannabinol (THC), the two naturally found compounds in the Cannabis plant.
The project is undertaken by the Central Institute of Medicinal And Aromatic Plants (CIMAP) and is going to explore the cultivation of low THC high CBD Cannabis strains at their office in Lucknow (Uttar Pradesh) and resource center in Pantnagar (Uttarakhand).
The Council of Scientific & Industrial Research (CSIR), together with CIMAP will start R&D work on genetic improvement of identification and selection of THC, CBD, and Cannabinioderpene– a rich strain-level genetic constituent of Ganja.
CBD is a non-psychoactive medicinal compound that has several therapeutic values whereas THC is the psychoactive component of Ganja that gives the “high” when consumed. Industrial Marijuana or Hemp can be refined for use in many commercial commodities like paper, textile, clothing, paint, biofuel, and animal feed.
It’s not just the beverage companies now that have interest in Cannabis. The trend is extending to health, beauty and wellness products as well. With new legislation on R&D of Cannabis plant, India will open up splendid opportunities to tap into the ready-to-boom Cannabis economy worldwide.